Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
narlaprevir + ritonavir + daclatasvir
- Development stage
- Unknown
- Lead developer
- R-Pharm
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
A fixed-dose combination of **narlaprevir**, **ritonavir**, and **daclatasvir** used as an **all-oral antiviral regimen** in the treatment of chronic hepatitis C virus (HCV) genotype 1b infection. Narlaprevir is a protease inhibitor targeting the HCV NS3/4A protease, daclatasvir is an NS5A inhibitor blocking viral RNA replication and assembly, and ritonavir is used as a pharmacokinetic enhancer (boosting narlaprevir levels by CYP3A4 inhibition)[1][2][3][4][7]. The regimen is administered orally and has demonstrated sustained virologic response (SVR12) rates of approximately 90% in phase 2 studies of treatment-naïve, genotype 1b HCV patients without specific NS5A resistance mutations[1][2][3][4][7].
- Brand names
- no unique brand name for the combination
- Other names
- narlaprevir/ritonavir/daclatasvir
02
Targets
NS3/4A (Hepatitis C virus nonstructural protein 3/4A serine protease)NS5A (Hepatitis C virus nonstructural protein 5A (genotype 1b))CYP3A4 (Cytochrome P450 3A4)
Beyond the preview
Go deeper on narlaprevir + ritonavir + daclatasvir.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on narlaprevir + ritonavir + daclatasvir.